Recent Updates
Recently added Catalysts
JSPR Negative Sentiment Score: 20/100

JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. and Encourages Investors to Contact the Firm

Key Takeaway: Jasper Therapeutics, Inc. is currently facing a class action lawsuit filed in the Northern District of California. The lawsuit alleges that Jasper made false statements regarding its business operations and compliance policies during the class period from November 30, 2023, to July 3, 2025. Key allegations include the company's failure to ensure that third-party manufacturers complied with regulations, which may negatively affect clinical trial results and the commercialization of its products. Affected investors have until November 18, 2025, to apply as lead plaintiffs.

Market Sentiment Analysis

CONCERNS & RISKS

  • Jasper is facing a class action lawsuit alleging false and misleading business practices.
  • The lawsuit claims that Jasper lacked adequate controls ensuring third-party manufacturers followed regulations.
  • There are concerns about the impact on clinical results and financial prospects of Jasper's products, including briquilimab.
  • Potential cost-reduction measures may disrupt the Company's operations and growth.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Jasper (JSPR) To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ:JSPR) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Jasper securities between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”).
Investors have until November 18, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company's products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Jasper shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

Who should contact Brandon Walker regarding Jasper losses?

Investors who acquired Jasper securities between November 30, 2023, and July 3, 2025.

What is the deadline to apply as lead plaintiff?

The deadline to apply is November 18, 2025.

What allegations are made in the class action lawsuit?

The lawsuit claims Jasper made false statements about its operations and compliance.

How can investors share information about their losses?

Investors can contact Brandon Walker or Marion Passmore via email or phone.

What type of law firm is Bragar Eagel & Squire, P.C.?

It is a nationally recognized law firm representing investors in complex litigation.

Last updated: Sep 30, 2025